Amerikanische Gesellschaft für Hirudotherapie

Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia and thrombosis.

Review published in The Annals of thoracic surgery (2000)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewKlinische StudienArzneimittelentwicklungFollis et al. · The Annals of thoracic surgery, 2000

Abstract

Heparin-induced thrombocytopenia and thrombosis (HITT) is an immunomediated disorder induced by the administration of heparin for therapeutic purposes. The presence of this condition in patients requiring full heparinization for cardiopulmonary bypass constitutes a formidable challenge for the cardiac surgeon. In this review, the clinical and experimental experience described in the literature are discussed in the perspective of the normal coagulation and the pathophysiology of HITT and in the light of a variety of old and new alternative anticoagulants.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsBlood Coagulation TestsCardiopulmonary BypassHeparinHumansThrombocytopeniaThrombosis

Zusammenfassung

Heparin-induced thrombocytopenia and thrombosis (HITT) is an immunomediated disorder induced by the administration of heparin for therapeutic purposes. The presence of this condition in patients requiring full heparinization for cardiopulmonary bypass constitutes a formidable challenge for the cardiac surgeon.

Warum dies für die Hirudotherapie relevant ist

This review discusses the clinical challenge of performing cardiopulmonary bypass in patients with heparin-induced thrombocytopenia and thrombosis (HITT), an immunomediated disorder caused by heparin administration. The authors review clinical and experimental experience with various old and new alternative anticoagulants, framed within the context of normal coagulation physiology and HITT pathophysiology. The abstract does not mention leeches, hirudin, leech-derived molecules, or hirudotherapy at any point. Consequently, the article has no direct connection to the American Society of Hirudotherapy's domain based on the abstract, and any relevance would be limited to general background on anticoagulation management that does not specifically involve leech-based therapies.

Zitation

Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia and thrombosis.

Follis et al. · The Annals of thoracic surgery, 2000

DOI

Verwandter klinischer Kontext

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Clinical EvidenceClinical ApplicationsDrug PipelineDrug DevelopmentDirect Thrombin InhibitorsMicrosurgery OutcomesSurgeryAnticoagulation CompoundsHemostasisCardiovascularCardiologyOtolaryngologyPulmonology

Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.